Author: Prelude Therapeutics, Incorporated

Posted Date:

March 17, 2026

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

Prelude Therapeutics, Incorporated

March 17, 2026
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Prelude Therapeutics, Incorporated

March 10, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Prelude Therapeutics, Incorporated

February 3, 2026